ADVFN Logo

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for discussion Register to chat with like-minded investors on our interactive forums.

FAB Fusion Antibodies Plc

3.85
0.00 (0.00%)
Last Updated: 08:00:00
Delayed by 15 minutes
Share Name Share Symbol Market Type Share ISIN Share Description
Fusion Antibodies Plc LSE:FAB London Ordinary Share GB00BDQZGK16 ORD 4P
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  0.00 0.00% 3.85 3.80 3.90 3.85 3.85 3.85 14,293 08:00:00
Industry Sector Turnover Profit EPS - Basic PE Ratio Market Cap
Pharmaceutical Preparations 2.9M -2.6M -0.0437 -0.88 2.29M

Fusion Antibodies PLC Director/PDMR Shareholding (0499A)

24/09/2020 2:39pm

UK Regulatory


Fusion Antibodies (LSE:FAB)
Historical Stock Chart


From Mar 2019 to Mar 2024

Click Here for more Fusion Antibodies Charts.

TIDMFAB

RNS Number : 0499A

Fusion Antibodies PLC

24 September 2020

Fusion Antibodies plc

("Fusion" or the "Company")

Director/PDMR Shareholding

Fusion Antibodies plc (AIM: FAB), specialists in pre-clinical antibody discovery, engineering and supply for both therapeutic drug and diagnostic applications, has been notified that on 23 September 2020, Alan Mawson, Non-Executive Director, sold 20,000 ordinary shares in the Company ("Ordinary Shares") from his pension fund at a price of 180 pence per Ordinary Share.

Following this sale, Alan Mawson has a direct and indirect interest in 124,000 Ordinary Shares, representing approximately 0.49 per cent. of the Company's issued share capital. Alan Mawson is also a Non-Executive Director of Clarendon Fund Managers Limited ("Clarendon") and sits on Clarendon's investment committee. Clarendon is the fund manager for Nitech Growth Fund LP which holds 358,850 Ordinary Shares and Viridian Growth Fund LP which holds 1,831,500 Ordinary Shares.

The following notification, made in accordance with the requirements of the EU Market Abuse Regulation, gives further details.

 
 1    Details of the person discharging managerial responsibilities 
       / person closely associated 
 a)   Name                        Alan Mawson 
     --------------------------  ---------------------------------------------- 
 2    Reason for the notification 
     -------------------------------------------------------------------------- 
 a)   Position/status             Non-Executive Director 
     --------------------------  ---------------------------------------------- 
 b)   Initial notification        Initial notification 
       /Amendment 
     --------------------------  ---------------------------------------------- 
 3    Details of the issuer, emission allowance market participant, 
       auction platform, auctioneer or auction monitor 
     -------------------------------------------------------------------------- 
 a)   Name                        Fusion Antibodies plc 
     --------------------------  ---------------------------------------------- 
 b)   LEI                         213800KBAYRC9VOQ9V39 
     --------------------------  ---------------------------------------------- 
 4    Details of the transaction(s): section to be repeated for 
       (i) each type of instrument; (ii) each type of transaction; 
       (iii) each date; and (iv) each place where transactions 
       have been conducted 
     -------------------------------------------------------------------------- 
 a)   Description of the          Ordinary shares of 4p each in Fusion 
       financial instrument,       Antibodies plc 
       type of instrument          Identification code (ISIN) for Fusion 
       Identification code         Antibodies plc ordinary shares: GB00BDQZGK16 
     --------------------------  ---------------------------------------------- 
 b)   Nature of the transaction   Sale of shares 
     --------------------------  ---------------------------------------------- 
 c)   Price(s) and volume(s)        Price(s)   Volume(s) 
                                     180p       20,000 
                                               ---------- 
     --------------------------  ---------------------------------------------- 
 d)   Aggregated information:     N/A 
       - Aggregated volume 
       - Price 
     --------------------------  ---------------------------------------------- 
 e)   Date of the transaction     23 September 2020 
     --------------------------  ---------------------------------------------- 
 f)   Place of the transaction    London Stock Exchange, XLON 
     --------------------------  ---------------------------------------------- 
 

Enquiries:

 
 Fusion Antibodies plc                                              www.fusionantibodies.com 
 Dr Paul Kerr, Chief Executive Officer                                       Via Walbrook PR 
 James Fair, Chief Financial Officer 
 
 
 Allenby Capital Limited                                            Tel: +44 (0)20 3328 5656 
 James Reeve / Asha Chotai (Corporate 
  Finance) 
 
 Tony Quirke (Sales) 
 
 Walbrook PR                               Tel: +44 (0)20 7933 8780 or fusion@walbrookpr.com 
 Anna Dunphy                                                        Mob: +44 (0)7876 741 001 
 Paul McManus                                                       Mob: +44 (0)7980 541 893 
 
 

About Fusion Antibodies plc

Fusion is a Belfast based contract research organisation ("CRO") providing a range of antibody engineering services for the development of antibodies for both therapeutic drug and diagnostic applications.

The Company's ordinary shares were admitted to trading on AIM on 18 December 2017. Fusion provides a broad range of services in antibody generation, development, production, characterisation and optimisation. These services include antigen expression, antibody production, purification and sequencing, antibody humanisation using Fusion's proprietary CDRx (TM) platform and the production of antibody generating stable cell lines to provide material for use in clinical trials. Since 2012, the Company has successfully sequenced and expressed over 250 antibodies and successfully completed over 100 humanisation projects and has an international, blue-chip client base, which has included eight of the top 10 global pharmaceutical companies by revenue.

The Company was established in 2001 as a spin out from Queen's University Belfast. The Company's mission is to enable pharmaceutical and diagnostic companies to develop innovative products in a timely and cost-effective manner for the benefit of the global healthcare industry. Fusion Antibodies provides a broad range of services in antibody generation, development, production, characterisation and optimisation.

Fusion Antibodies growth strategy is based on combining the latest technological advances with cutting edge science to deliver new platforms that will enable Pharma and Biotechs get to the clinic faster, with the optimal drug candidate and ultimately speed up the drug development process.

The global monoclonal antibody therapeutics market was valued at $135.4 billion in 2018 and is forecast to surpass $212.6 billion in 2022, an increase at a CAGR of 12.0 per cent. for the period 2018 to 2022. In 2017, seven of the world's ten top selling drugs were antibody-based therapeutics with the combined annual sales of these drugs exceeding $63.2 billion.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

DSHSEAFDLESSEDU

(END) Dow Jones Newswires

September 24, 2020 09:39 ET (13:39 GMT)

1 Year Fusion Antibodies Chart

1 Year Fusion Antibodies Chart

1 Month Fusion Antibodies Chart

1 Month Fusion Antibodies Chart

Your Recent History

Delayed Upgrade Clock